| Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy EA Collisson, A Sadanandam, P Olson, WJ Gibb, M Truitt, S Gu, J Cooc, ... Nature medicine 17 (4), 500-503, 2011 | 1738 | 2011 |
| A central role for RAF→ MEK→ ERK signaling in the genesis of pancreatic ductal adenocarcinoma EA Collisson, CL Trejo, JM Silva, S Gu, JE Korkola, LM Heiser, ... Cancer discovery 2 (8), 685-693, 2012 | 334 | 2012 |
| Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections MS Draz, BA Fang, P Zhang, Z Hu, S Gu, KC Weng, JW Gray, FF Chen Theranostics 4 (9), 872, 2014 | 251 | 2014 |
| Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer W Ngamcherdtrakul, J Morry, S Gu, DJ Castro, SM Goodyear, ... Advanced functional materials 25 (18), 2646-2659, 2015 | 193 | 2015 |
| The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer Z Hu, G Huang, A Sadanandam, S Gu, ME Lenburg, M Pai, N Bayani, ... Breast cancer research 12, 1-15, 2010 | 158 | 2010 |
| Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis J Morry, W Ngamcherdtrakul, S Gu, SM Goodyear, DJ Castro, MM Reda, ... Biomaterials 66, 41-52, 2015 | 71 | 2015 |
| Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery W Ngamcherdtrakul, T Sangvanich, M Reda, S Gu, D Bejan, W Yantasee International journal of nanomedicine, 4015-4027, 2018 | 59 | 2018 |
| Targeted treatment of metastatic breast cancer by PLK1 siRNA delivered by an antioxidant nanoparticle platform J Morry, W Ngamcherdtrakul, S Gu, M Reda, DJ Castro, T Sangvanich, ... Molecular cancer therapeutics 16 (4), 763-772, 2017 | 59 | 2017 |
| PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer M Reda, W Ngamcherdtrakul, S Gu, DS Bejan, N Siriwon, JW Gray, ... Cancer letters 467, 9-18, 2019 | 57 | 2019 |
| Therapeutic siRNA for drug-resistant HER2-positive breast cancer S Gu, Z Hu, W Ngamcherdtrakul, DJ Castro, J Morry, MM Reda, JW Gray, ... Oncotarget 7 (12), 14727, 2016 | 42 | 2016 |
| Current development of targeted oligonucleotide-based cancer therapies: perspective on HER2-positive breast cancer treatment W Ngamcherdtrakul, DJ Castro, S Gu, J Morry, M Reda, JW Gray, ... Cancer treatment reviews 45, 19-29, 2016 | 30 | 2016 |
| Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment S Gu, W Ngamcherdtrakul, M Reda, Z Hu, JW Gray, W Yantasee PloS one 13 (6), e0198141, 2018 | 24 | 2018 |
| Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer Z Hu, JH Mao, C Curtis, G Huang, S Gu, L Heiser, ME Lenburg, ... Breast cancer research 18, 1-12, 2016 | 12 | 2016 |
| Lanthanide-loaded nanoparticles as potential fluorescent and mass probes for high-content protein analysis W Ngamcherdtrakul, T Sangvanich, S Goodyear, M Reda, S Gu, ... Bioengineering 6 (1), 23, 2019 | 9 | 2019 |
| Abstract 2020: A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer. Z Hu, J Mao, G Huang, W Kuo, M Lenburg, S Ziyad, J Korkola, N Bayani, ... Cancer Research 69 (24 Supplement), 2020-2020, 2009 | 2 | 2009 |
| Abstract 5572: Small molecular inhibitor of centromere-associated protein E (CENP-E), GSK923295A inhibits cell growth in breast cancer cells Z Hu, W Kuo, D Das, S Ziyad, S Gu, S Bhattacharya, A Wyrobek, N Wang, ... Cancer Research 69 (9 Supplement), 5572-5572, 2009 | 2 | 2009 |
| Nanoparticle Based RNAi Therapeutic to Overcome Intrinsic and Acquired Resistance in HER2+ Breast Cancer: A Dissertation S Gu Oregon Health & Science University, 2018 | | 2018 |
| 4th International Conference on Nanotek & Expo M Reda, W Yantasee, W Ngamcherdtrakul, S Gu, J Morry, S Goodyear, ... | | 2014 |
| P5. EXPERIMENTAL THERAPEUTICS S Gu, S Goodyear, W Ngamcherdtrakul, J Morry, T Sangvanich, D Castro, ... | | 2014 |
| Abstract LB-208: Small interfering RNA library screen to identify therapeutic transcription factor. Z Hu, S Gu, J Gray, J Rantala Cancer Research 73 (8_Supplement), LB-208-LB-208, 2013 | | 2013 |
Joe GrayBiomedical Engineering, Oregon Health and Science UniversityDirección de correo verificada de ohsu.edu
